Europe Drug Discovery Market Forecast 2022-2030

Europe Drug Discovery Market Forecast 2022-2030

KEY FINDINGS

The Europe drug discovery market is anticipated to project a CAGR of 6.90% during the forecast period, 2022-2030. The rising collaborations for drug discovery and development, advanced technologies, and increased R&D expenses influence market growth in the region.

MARKET INSIGHTS

Italy, Russia, France, Germany, the United Kingdom, Spain, Scandinavia, and Rest of Europe are analyzed for the Europe drug discovery market growth evaluation. In Germany, the pharmaceutical industry is witnessing increasing investments. Also, in 2019 the research-based pharmaceutical companies financed 499 clinical trials. In the same year, companies in pharma R&D were developing 640 biologics in clinical development, out of which 82% of Phase III assets were new biological entities. Biologicals development majorly prioritizes infectious diseases, immunology, and oncology.

In Italy, AIFA (Italian Medicines Agency) is the national authority that overlooks drugs regulations. It operates transparently and autonomously, adhering to the cost-effectiveness aspect, under the direction and vigilance of the Ministry of Health and the Ministry of Economy. Spain is a conducive country for developing clinical trials for new drugs. Its research and development model for new medicines is collaborative and gaining international prospects. Such aspects bring about research investment by pharmaceutical companies in the country.

Furthermore, high-end technological advancements, a skilled workforce, and the presence of prominent pharmaceutical players render Europe one of the leading markets for drug discovery. The presence of the European Medical Agency (EMA) and the European Commission laws further contribute to the region’s market prospects.

COMPETITIVE INSIGHTS

Some of the major companies operating in the market include Novartis AG, Johnson & Johnson, Merck & Co Inc, Pfizer Inc, etc.

Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments


1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations
2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
3. Market Dynamics
3.1. Key Drivers
3.1.1. Growing R&D For Tackling Several Diseases
3.1.2. Technological Advancements
3.2. Key Restraints
3.2.1. Extensive Time-consuming Process
3.2.2. Highly Regulated Market
3.2.3. Project Feasibility And Success Rate
4. Key Analytics
4.1. Impact Of Covid-19 On Drug Discovery Industry
4.2. Key Market Trends
4.3. Porter’s Five Forces Analysis
4.3.1. Buyers Power
4.3.2. Suppliers Power
4.3.3. Substitution
4.3.4. New Entrants
4.3.5. Industry Rivalry
4.4. Opportunity Matrix
4.5. Drug Discovery And Development Process
4.5.1. Drug Discovery And Development
4.5.2. Preclinical Research
4.5.3. Clinical Research
4.5.4. Regulatory Authority Review
4.5.5. Post Market Safety Monitoring
4.6. Regulatory Framework
5. Market By Drug Type
5.1. Small Molecule Drug
5.2. Biologic Drug
6. Market By Service
6.1. Chemical Services
6.2. Drug Metabolism And Pharmacokinetics Services
6.3. Biological Services
6.4. Other Pharmaceutical Services
7. Market By End-user
7.1. Pharmaceutical Companies
7.2. Contract Research Organizations
7.3. Research Institutes
7.4. Other End-users
8. Market By Technology
8.1. High Throughput Screening
8.2. Spectroscopy
8.3. Combinatorial Chemistry
8.4. Biochips
8.5. Pharmacogenomics And Pharmacogenetics
8.6. Bioinformatics
8.7. Metabolomics
8.8. Nanotechnology
8.9. Other Technologies
9. Geographical Analysis
9.1. Europe
9.1.1. Market Size & Estimates
9.1.2. Key Growth Enablers
9.1.3. Key Challenges
9.1.4. Key Players
9.1.5. Country Analysis
9.1.5.1. United Kingdom
9.1.5.2. Germany
9.1.5.3. France
9.1.5.4. Italy
9.1.5.5. Russia
9.1.5.6. Spain
9.1.5.7. Scandinavia
9.1.5.8. Rest Of Europe
10. Competitive Landscape
10.1. Key Strategic Developments
10.1.1. Mergers & Acquisitions
10.1.2. Product Launches & Developments
10.1.3. Partnerships & Agreements
10.1.4. Business Expansions & Divestitures
10.2. Company Profiles
10.2.1. Agilent Technologies Inc
10.2.2. Astrazeneca Plc
10.2.3. Bayer Ag
10.2.4. Charles River Laboratories International Inc
10.2.5. Eli Lilly And Company
10.2.6. Evotec Se
10.2.7. Glaxosmithkline Plc
10.2.8. Icon Plc
10.2.9. Iqvia Holdings Inc
10.2.10. Johnson & Johnson
10.2.11. Merck & Co Inc
10.2.12. Novartis Ag
10.2.13. Pfizer Inc
10.2.14. Roche Ag

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings